The right compound in the right assay at the right time: an integrated discovery DMPK strategy

被引:36
作者
Ballard, Peter [1 ]
Brassil, Patrick [2 ]
Bui, Khanh H. [3 ]
Dolgos, Hugues [4 ]
Petersson, Carl [5 ]
Tunek, Anders [4 ]
Webborn, Peter J. H.
机构
[1] AstraZeneca, Mereside, Alderley Pk SK10 4TG, Cheshire, England
[2] AstraZeneca, Gatehouse Pk, MA USA
[3] AstraZeneca, Wilmington, PA USA
[4] AstraZeneca, Molndal, Sweden
[5] AstraZeneca, Sodertalje, Sweden
关键词
Compound optimization; design-make-test-analyze cycles; human pharmacokinetic and dose predictions; CNS distribution; drug-drug interactions; clearance; absorption; metabolites; transporters; DRUG-DRUG INTERACTIONS; CENTRAL-NERVOUS-SYSTEM; IN-SILICO PREDICTION; BLOOD-BRAIN-BARRIER; INTESTINAL 1ST-PASS METABOLISM; HUMAN CYTOCHROME-P450 2D6; INTRINSIC CLEARANCE DATA; PLASMA-PROTEIN BINDING; HUMAN RENAL CLEARANCE; MARKETED ORAL-DRUGS;
D O I
10.3109/03602532.2012.691099
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The high rate of attrition during drug development and its associated high research and development (R&D) cost have put pressure on pharmaceutical companies to ensure that candidate drugs going to clinical testing have the appropriate quality such that the biological hypothesis could be evaluated. To help achieve this ambition, drug metabolism and pharmacokinetic (DMPK) science and increasing investment have been deployed earlier in the R&D process. To gain maximum return on investment, it is essential that DMPK concepts are both appropriately integrated into the compound design process and that compound selection is focused on accurate prediction of likely outcomes in patients. This article describes key principles that underpin the contribution of DMPK science for small-molecule research based on 15 years of discovery support in a major pharmaceutical company. It does not aim to describe the breadth and depth of DMPK science, but more the practical application for decision making in real-world situations.
引用
收藏
页码:224 / 252
页数:29
相关论文
共 149 条
[1]   State-of-the-art tools for computational site of metabolism predictions: Comparative analysis, mechanistical insights, and future applications [J].
Afzelius, Lovisa ;
Arnby, Catrin Hasselgren ;
Broo, Anders ;
Carlsson, Lars ;
Isaksson, Christine ;
Jurva, Ulrik ;
Kjellander, Britta ;
Kolmodin, Karin ;
Nilsson, Kristina ;
Raubacher, Florian ;
Weidolf, Lars .
DRUG METABOLISM REVIEWS, 2007, 39 (01) :61-86
[2]   A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[3]   Predicting Circulating Human Metabolites: How Good Are We? [J].
Anderson, Shelby ;
Luffer-Atlas, Debra ;
Knadler, Mary Pat .
CHEMICAL RESEARCH IN TOXICOLOGY, 2009, 22 (02) :243-256
[4]  
[Anonymous], 2008, GUID IND SAF TEST DR
[5]   Phase II failures: 2008-2010 [J].
Arrowsmith, John .
NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (05) :1-1
[6]   TRIAL WATCH Phase III and submission failures: 2007-2010 [J].
Arrowsmith, John .
NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (02) :1-1
[7]   CORRELATION BETWEEN ORAL-DRUG ABSORPTION IN HUMANS AND APPARENT DRUG PERMEABILITY COEFFICIENTS IN HUMAN INTESTINAL EPITHELIAL (CACO-2) CELLS [J].
ARTURSSON, P ;
KARLSSON, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 175 (03) :880-885
[8]   Caco-2 monolayers in experimental and theoretical predictions of drug transport (Reprinted from Advanced Drug Delivery Reviews, vol 22, pg 67-84, 1996) [J].
Artursson, P ;
Palm, K ;
Luthman, K .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 46 (1-3) :27-43
[9]  
Avdeef Alex, 2005, Expert Opin Drug Metab Toxicol, V1, P325, DOI 10.1517/17425255.1.2.325
[10]   Future of toxicology-metabolic activation and drug design: Challenges and opportunities in chemical toxicology [J].
Baillie, Thomas A. .
CHEMICAL RESEARCH IN TOXICOLOGY, 2006, 19 (07) :889-893